Investment
Features
FeesSafety
Academy
More
Pluang+

Compare iShares MSCI Canada (TSX) (EWC) vs Merck & Co., Inc. (MRK) Price & Performance

iShares MSCI Canada (TSX)Trade
Merck & Co., Inc.Trade

Price performance (Past 24H)

Key statistics

iShares MSCI Canada (TSX) vs Merck & Co., Inc. — how do they compare? iShares MSCI Canada (TSX) trades at $61.51, while Merck & Co., Inc. trades at $130.29 (market cap $323.00B). The key difference: Merck & Co., Inc. pays a 2.6% dividend while iShares MSCI Canada (TSX) pays none. Which is the better fit depends on your goals.

EWCMRK
Sector
Broad Market / FactorHealth
52-Week High
$61.51$131.84
52-Week Low
$47.00$77.60
Market Cap
$323.00B
Enterprise Value
$369.77B
Dividend Yield
2.6%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

iShares MSCI Canada (TSX)

EWC, the iShares MSCI Canada ETF, trades at $61.30, up 0.99% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The fund faces headwinds from renewed U.S.-Canada trade tensions, including 50% tariffs announced in July 2026, though bullish analyst views highlight resilience due to energy and potash exclusions. Key financial ratios are unavailable in the provided data.

Outlook is mixed: technical strength supports near-term gains, but trade policy risks and overbought conditions warrant caution. Investment appeal hinges on Canada's resource-heavy economy navigating tariffs, with diversification benefits for U.S. investors. Risks include escalated trade war impacts on Canadian exports and market volatility.

Merck & Co., Inc.

MRK trades at $130.90, up 1.81% today, with a bullish technical signal and strong institutional buying interest. The stock shows robust fundamentals with revenue of $65.01B in 2025 and net income of $18.25B, though a high P/E of 104.74 indicates premium valuation. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives.

Outlook is positive with a consensus price target of $139.90, offering ~7% upside, supported by 67.57% analyst buy ratings. Risks include integration challenges from acquisitions and patent expirations, but strong cash flow and dividend payments provide stability. Investors may find value in Merck's market leadership and pipeline expansion, though valuation metrics warrant caution.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About iShares MSCI Canada (TSX)

EWC is a country-specific ETF that tracks the performance of the Canadian equity market. It provides exposure to large and mid-sized companies in Canada, with heavy concentrations in financials and energy, including Royal Bank of Canada, Shopify, and Enbridge.

Read more on EWC

About Merck & Co., Inc.

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.

Read more on MRK